N,N-Dimethyl-2-(2-sulfanyladamantan-2-yl)acetamide | 618112-68-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N,N-Dimethyl-2-(2-sulfanyladamantan-2-yl)acetamide
• 英文别名: N,N-dimethyl-2-(2-sulfanyl-2-adamantyl)acetamide
• CAS: 618112-68-8
• 化学式: C₁₄H₂₃NOS
• 分子量: 253.409
• InChiKey: UDSGIGSREBZZKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N-Dimethyl-2-(2-sulfanyladamantan-2-yl)acetamide 在 亚硝酸特丁酯 作用下， 以 二氯甲烷 、 水 为溶剂， 以80%的产率得到N,N-dimethyl-2-(2-(nitrosothio)adamantan-2-yl)acetamide
  参考文献：
  名称：

  Nitric oxide donors, compositions and methods of use related applications

  摘要：

  该发明描述了新颖的一氧化氮供体和至少含有一个一氧化氮供体的新型组合物。该发明还提供了至少含有一个一氧化氮供体的新型组合物，以及可选地至少含有一个治疗剂。该发明的化合物和组合物也可以与基质结合。该发明还提供了治疗心血管疾病的方法，用于抑制血液暴露于医疗器械引起的血小板聚集和血小板粘附，用于治疗由于异常细胞增殖导致的病理状况；移植排斥、自身免疫、炎症、增殖、过度增殖、血管疾病；用于减少瘢痕组织或抑制伤口收缩，特别是通过给予一氧化氮供体的预防性和/或治疗性治疗以及至少一个治疗剂的组合来治疗再狭窄的方法。该发明还提供了治疗炎症、疼痛、发热、胃肠道疾病、呼吸道疾病和性功能障碍的方法。一氧化氮供体可以捐赠、转移或释放一氧化氮，并/或提高内源性内皮血管舒张因子的水平，并/或刺激内源性一氧化氮的合成和/或是一氧化氮合酶的底物，能够在生理条件下释放一氧化氮或间接地将一氧化氮传递或转移至靶向部位。治疗剂可以选择性地用至少一个NO和/或NO2基（即亚硝基化和/或亚硝化）替代。该发明还提供了至少含有一个一氧化氮供体和/或至少一个治疗剂的新型组合物和试剂盒。

  公开号：

  US20030203915A1
• 作为产物：
  描述：

  金刚烷-2-硫酮 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 环己烷 为溶剂， 反应 5.01h， 生成 N,N-Dimethyl-2-(2-sulfanyladamantan-2-yl)acetamide
  参考文献：
  名称：

  Combination of Paclitaxel and Nitric Oxide as a Novel Treatment for the Reduction of Restenosis

  摘要：

  The combination of a nitric oxide (NO) donor and a paclitaxel-NO donor conjugate coated on a vascular stent was tested in a rabbit iliac artery model of stenosis as a potential therapy for restenosis. Paclitaxel was conjugated with a NO donor at the 7-position to give compound 7. An adamantane-based NO donor 14 was synthesized and combined with 7 to provide a burst of NO in the first few critical hours following injury to the vessel wall. Both 7 and 14 demonstrated antiproliferative activity (IC50 = 20 nM and 15 muM, respectively) and antiplatelet activity (IC50 = 10 and 1 muM, respectively). Stents were coated with a layer of a polymer containing test compounds. The total amount of NO eluted from the stents after a 6 h implantation in the rabbit iliac artery was 35,70, 95%, and 69% of the original content for the stents coated with 7, 14, and the combination of 7 and 14, respectively. The antistenotic activity of 7 and 14 was determined in a 28-day rabbit model with two control groups (uncoated stents and polymer-coated stents) and two study groups (paclitaxel-coated stents and stents coated with the combination of 7 and 14). Polymer-coated stents caused inflammation and increased stenosis by 39% when compared to the uncoated stents. The stents coated with 7 plus 14 were as good as the uncoated stents, 41% better than the polymer-coated stents and 34% better than the paclitaxel-coated stents. These data indicate a beneficial effect of adding NO to an antiproliferative agent (paclitaxel) and suggest a potential therapeutic combination for the treatment of stenotic vessel disease.

  DOI：

  10.1021/jm0304111

文献信息

• Nitric oxide donors, compositions and methods of use related applications
  申请人：——

  公开号：US20030203915A1

  公开（公告）日：2003-10-30

  The invention describes novel nitric oxide donors and novel compositions comprising at least one nitric oxide donor. The invention also provides novel compositions comprising at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for the inhibition of platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative, vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering the nitric oxide donor optionally in combination with at least one therapeutic agent. The invention also provides methods for treating inflammation, pain, fever, gastrointestinal disorders, respiratory disorders and sexual dysfunctions. The nitric oxide donors donate, transfer or release nitric oxide, and/or elevate endogenous levels of endothelium-derived relaxing factor, and/or stimulate endogenous synthesis of nitric oxide and/or are substrates for nitric oxide synthase and are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The therapeutic agent can optionally be substituted with at least one NO and/or NO 2 group (i.e., nitrosylated and/or nitrosated). The invention also provides novel compositions and kits comprising at least one nitric oxide donor and/or at least one therapeutic agent.

  该发明描述了新颖的一氧化氮供体和至少含有一个一氧化氮供体的新型组合物。该发明还提供了至少含有一个一氧化氮供体的新型组合物，以及可选地至少含有一个治疗剂。该发明的化合物和组合物也可以与基质结合。该发明还提供了治疗心血管疾病的方法，用于抑制血液暴露于医疗器械引起的血小板聚集和血小板粘附，用于治疗由于异常细胞增殖导致的病理状况；移植排斥、自身免疫、炎症、增殖、过度增殖、血管疾病；用于减少瘢痕组织或抑制伤口收缩，特别是通过给予一氧化氮供体的预防性和/或治疗性治疗以及至少一个治疗剂的组合来治疗再狭窄的方法。该发明还提供了治疗炎症、疼痛、发热、胃肠道疾病、呼吸道疾病和性功能障碍的方法。一氧化氮供体可以捐赠、转移或释放一氧化氮，并/或提高内源性内皮血管舒张因子的水平，并/或刺激内源性一氧化氮的合成和/或是一氧化氮合酶的底物，能够在生理条件下释放一氧化氮或间接地将一氧化氮传递或转移至靶向部位。治疗剂可以选择性地用至少一个NO和/或NO2基（即亚硝基化和/或亚硝化）替代。该发明还提供了至少含有一个一氧化氮供体和/或至少一个治疗剂的新型组合物和试剂盒。
• NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE
  申请人：Nitromed, Inc.

  公开号：EP1497268A2

  公开（公告）日：2005-01-19
• EP1497268A4
  申请人：——

  公开号：EP1497268A4

  公开（公告）日：2006-01-18
• [EN] NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE<br/>[FR] DONNEURS DE MONOXYDE D'AZOTE, COMPOSITIONS ET PROCEDES D'UTILISATION, APPLICATIONS CORRESPONDANTES
  申请人：NITROMED INC

  公开号：WO2003086282A2

  公开（公告）日：2003-10-23

  The invention describes novel nitric oxide donors and novel compositions comprising at least one nitric oxide donor. The invention also provides novel compositions comprising at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for the inhibition of platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative, vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering the nitric oxide donor optionally in combination with at least one therapeutic agent. The invention also provides methods for treating inflammation, pain, fever, gastrointestinal disorders, respiratory disorders and sexual dysfunctions. The nitric oxide donors donate, transfer or release nitric oxide, and/or elevate endogenous levels of endothelium-derived relaxing factor, and/or stimulate endogenous synthesis of nitric oxide and/or are substrates for nitric oxide synthase and are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The therapeutic agent can optionally be substituted with at least one NO and/or NO2 group (i.e., nitrosylated and/or nitrosated). The invention also provides novel compositions and kits comprising at least one nitric oxide donor and/or at least one therapeutic agent.
• Combination of Paclitaxel and Nitric Oxide as a Novel Treatment for the Reduction of Restenosis
  作者：Chia-En Lin、David S. Garvey、David R. Janero、L. Gordon Letts、Przemyslaw Marek、Stewart K. Richardson、Diana Serebryanik、Matthew J. Shumway、S. William Tam、A. Mark Trocha、Delano V. Young

  DOI：10.1021/jm0304111

  日期：2004.4.1

  The combination of a nitric oxide (NO) donor and a paclitaxel-NO donor conjugate coated on a vascular stent was tested in a rabbit iliac artery model of stenosis as a potential therapy for restenosis. Paclitaxel was conjugated with a NO donor at the 7-position to give compound 7. An adamantane-based NO donor 14 was synthesized and combined with 7 to provide a burst of NO in the first few critical hours following injury to the vessel wall. Both 7 and 14 demonstrated antiproliferative activity (IC50 = 20 nM and 15 muM, respectively) and antiplatelet activity (IC50 = 10 and 1 muM, respectively). Stents were coated with a layer of a polymer containing test compounds. The total amount of NO eluted from the stents after a 6 h implantation in the rabbit iliac artery was 35,70, 95%, and 69% of the original content for the stents coated with 7, 14, and the combination of 7 and 14, respectively. The antistenotic activity of 7 and 14 was determined in a 28-day rabbit model with two control groups (uncoated stents and polymer-coated stents) and two study groups (paclitaxel-coated stents and stents coated with the combination of 7 and 14). Polymer-coated stents caused inflammation and increased stenosis by 39% when compared to the uncoated stents. The stents coated with 7 plus 14 were as good as the uncoated stents, 41% better than the polymer-coated stents and 34% better than the paclitaxel-coated stents. These data indicate a beneficial effect of adding NO to an antiproliferative agent (paclitaxel) and suggest a potential therapeutic combination for the treatment of stenotic vessel disease.